Sanofi, Regeneron’s Libtayo improves survival in cervical cancer patients

Sanofi and Regeneron’s PD-1 inhibitor Libtayo has demonstrated positive overall survival (OS) results in a Phase III trial in advanced cervical cancer.

The Phase III trial, evaluating Libtayo (cemiplimab) compared to chemotherapy in recurrent/metastatic cervical cancer patients who had been previously treated with chemotherapy, will be stopped early based on a recommendation made by the Independent Data Monitoring Committee (IDMC).